//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Registration

Online Registration is Open!
Register by Friday, July 18 to Save Up to $200!
»Pricing Chart

Add to Outlook Calendar

Find Another IBC Event

Cell Line Development & Engineering

CSS

Improve All Aspects of Bioproduct Development by Leveraging Cutting-Edge Technical and Process Innovation

September 08-10, 2014 · DoubleTree by Hilton Berkeley Marina · Berkeley, CA

Agenda

Agenda

Monday, September 8, 2014

7:00
Registration and Coffee

8:00
Chairperson's Opening Remarks
Hilary Metcalf, Ph.D., Head of Process Development, Lonza, United Kingdom

Progress in Host Cell Engineering

8:15
New Data
Approaches to Engineer Virus Resistance into CHO Cell Lines
Abstract not available at time of print.
Kevin J. Kayser, Ph.D., Director, Cell Sciences and Development, SAFC

8:45
Case StudyNew Data
Integrative -OMICS Data Approach on the Road to Understand MIRNA-Engineered CHO Cell Phenotypes
MicroRNA (miRNA) engineering in CHO cells is a promising strategy to improve recombinant protein production. We integrated miRNA, mRNA and protein expression data of miRNA-engineered cells and developed a bioinformatics pipeline for handling of such datasets. This multi-omics approach is necessary to understand miRNA activity in cells were no a priori knowledge of their interactions is available.
Vaibhav Jadhav, Ph.D., Department of Biotechnology, University of Natural Resources and Life Sciences, Austria

9:15
Case StudyNew Data
Improving Mitochondrial Activity Via miRNA Manipulation
MicroRNAs are now recognized as a fundamental layer of genetic regulation within cells. Several groups have shown that microRNA manipulation can be utilized to impact on CHO cell growth and productivity. We will present data on the impact of depleting the expression of an entire microRNA cluster and how the phenotypic outcome may be linked to mitochondrial activity.
Niall Baron, Ph.D., Senior Scientist, Dublin City University, Ireland

9:45
Case StudyNew Data
Genome Engineering Using Larger or Multiple Inserts
Utilizing the data from the completed CHO-M Genome and Transcriptome project, we identified areas in the CHO-M secretory pathway where key secretory pathways proteins levels were either missing or expressed at inappropriate levels. We concurrently developed a vector system that allowed us to engineer the CHO-M secretory pathway by inserting multiple genes into the genome simultaneously. Using this technology, we generated a panel of CHO-based libraries consisting of multiple genes addressing key issues associated with effective translation, translocation and secretion. A case study evaluating co-expression of multiple chaperones simultaneously on recombinant protein production levels will be presented.
Pierre-Alain Girod, Ph.D., Chief Scientific Officer, Selexis SA, Switzerland

10:15
Networking Refreshment Break in Poster & Exhibit Hall

Systems Biology for CHO Cell Engineering

Featured Presentation

10:45
New Data
Integrating Omics Data with Systems Biology Analysis to Engineer Protein Secretion in CHO Cells
Complex targeted efforts in bioprocess and CHO cell line engineering can be approached using genomic sequences of CHO-K1 and the Chinese hamster. We are using these resources to identify mutations and construct genome-scale models to predict the practical limits protein production of CHO. Furthermore, these tools are platforms for - omic data analysis, providing insights into the molecular basis of CHO cell phenotypes.
Nathan E. Lewis, Ph.D., Assistant Professor of Pediatrics, University of California, San Diego

11:15
Systems and Synthetic Biotechnology Platform for Designing HEK293 Cells
RNA interference has emerged as a powerful tool for cell line engineering. Utilizing the high-throughput RNAi screen platform, miRNAs that can improve protein expression in HEK293 cells were identified. Two model proteins were investigated: luciferase and neurotensin receptor type I, which is a class A G-protein-coupled receptor. Data from both screens was combined for discovery of common important factors that can boost protein expression in general.
Su Xiao, Ph.D. Candidate, Chemical and Biomolecular Engineering, Johns Hopkins University

11:45
New Data
Precision Genome Engineering and Synthetic Biology: New Tools for Designing and Editing Genomes
Recent advances in sequencing, bioinformatics and genomic editing have changed how we approach development of new bioproduction platforms. Additionally, we can now efficiently target expression cassettes to specific locations in the genome to take advantage of 'safe harbor' loci where stable, high level expression would be predicted. By applying principles from synthetic biology such as metabolic modeling, next generation sequencing and gene synthesis and genome editing, efficient creation of highly optimized bioproduction platform cell lines is within our reach. The Thermo Fisher Scientific cell engineering group is building a comprehensive toolbox to enable the entire workflow from analysis to engineering. We will present the latest progress toward safe harbor site identification using nextgen sequencing as well as gene insertion and editing using our portfolio of editing tools.
Jonathan D. Chestnut, Ph.D., Senior Director, Synthetic Biology R&D, Thermo Fisher Scientific

12:15
Networking Luncheon in Poster & Exhibit Hall

1:25
Chairperson's Remarks
Kevin McCarthy, Ph.D., Group Leader for Cell Sciences, EMD Serono Inc. (invited)

Applying Automated and High Throughput Platforms for Process Intensification

1:30
New Data
Microfluidic-Based Sorting of High Producer Cells
The occurrence of highly expressing cells is increased by the use of e.g. MAR elements and by efficient selection procedures, but selection of the best cell clones is still required. Automated clone picking devices are useful but have a limited throughput. I will describe how a microfluidic device may enrich polyclonal CHO populations in cells that secrete recombinant proteins at high levels.
Nicolas Mermod, Ph.D., Professor, University of Lausanne, Switzerland

2:00
New Data
Implementation of a Predictive Screening Strategy for Cell Cloning by Automation and Parallelization
For the implementation of Bayer's new cell line development system a new automation friendly cell line development workflow was created aiming an enhanced predictivity for scale-up while enabling automated screening of high numbers of different clones. A compact flexible automation platform as key component with integrated data management connected to a Biologics data platform as well as a small scale bioreactor system was established.
Anke Mayer-Bartschmid, Ph.D., Senior Scientist, Cell Line Development, Cell and Protein Sciences, Bayer HealthCare AG, Germany

2:30
Screening of Clonal Cell Lines in Micro-Scale Fed Batch Cultures
We describe a method used in early stage process development for the screeing of candidate cell lines with the aim to match specific performance and product quality features. The approach which is based on micro-scale cultures was found to be particularly fast and resource efficient. Moreover, the outcome correlated with confirmations performed in larger call culture volumes such as lab-scale bioreactors.
Matthieu Stettler, Ph.D., Manager, Upstream Process Development, Merck Serono SA, Switzerland

3:00
Case Study
High-Throughput Ion Exchange Purification of Positively Charged Recombinant Protein in the Presence of Negatively Charged Dextran Sulfate
High-throughput small-scale protein purification (SSP) is critical for product quality analyses in cell line and process development. We develop an SSP to purify a positively charged recombinant growth factor P1. The major challenges here are caused by strong ionic interaction between P1 and negatively charged dextran sulfate. To solve this problem, we develop a two-step SSP using Q Sepharose FF and SP Sepharose XL resins. The SSP has a yield of 78% and does not affect critical product quality attributes.
Lam Raga Anggara Markely, Ph.D., Scientist II, Biogen Idec

3:30
Networking Refreshment Break in Poster & Exhibit Hall

Keynote Presentations

4:00
New Data
Kelvin H. Lee, Ph.D. The Genome as an Enabler of Product Attribute Control
Genome sequencing provides basic knowledge to better understand and control cells and process conditions for enabling product attribute control. Our community has not clearly defined the relationship between the relevant basic science and product attribute control. We will discuss relevant analogies from other disciplines the impact of a community-wide effort to establish a reference genome.
Kelvin Lee, Ph.D., Gore Professor of Chemical Engineering, Delaware Biotechnology Institute Faculty Fellow, University of Delaware

4:30
New Data
David C. James, Ph.D. Design of Next Generation CHO Cell Factories
What are the enabling cellular mechanisms that underpin the ideal CHO cell manufacturing phenotype. Moreover, how do we design and engineer bespoke CHO cells specifically able to manufacture particular difficult-to-express proteins? The new concepts and tools of systems and synthetic biology offer a new paradigm for rapid design and construction of intrinsically fit-for-purpose cell factories. I will describe new synthetic promoter technology that enables precise control of recombinant gene expression in CHO cells over two orders of magnitude and how new production processes for DTE proteins could specifically benefit from predictable control of recombinant gene expression.
David James, Ph.D., Professor of Bioprocess Engineering, Department of Chemical and Process Engineering, University of Sheffield, United Kingdom

5:00
Rohini Deshpande, Ph.D. Accelerated Path to Probe the Biology through Deferred Cloning and Applying Platform Manufacturing Processes
We have developed a robust cell line development strategy and a drug substance process platform that meets the needs of clinical entry and commercialization. The expression system is built to deliver amplified pools with high expression to consistently generate toxicological and clinical material with desired product quality attribute profile for early phase studies. These amplified pools are cloned to generate a commercially suitable clonally derived cell bank for pivotal studies and commercial launch. In this talk we will present process and product quality data from pools and clones and propose to defer cloning until commercial process development. We will share the benefits of this accelerated path in bringing forward meaningful therapies to patients.
Rohini Deshpande, Ph.D., Executive Director, Drug Substance Development, Amgen, Inc

5:30
Networking Cocktail Reception in Poster & Exhibit Hall

Tuesday, September 9, 2014

8:00
Chairperson's Opening Remarks
Rodney Combs, M.S., Associate Research Fellow, Bioprocess R&D, Culture Process Development, World Wide Pharmaceutical Sciences, Pfizer Inc.

Improving Product Quality and Assuring Clonality and Stability

8:15
New Data
Engineering a Mammalian Cell Line Toolbox that Exhibits Multiple Productivity and Product Quality Profiles
Although the simplicity of having a single, well-characterized host upon which to initiate cell line engineering has many advantages, a one size fits all approach does have drawbacks. We have engineered a Cell Line Toolbox composed of a variety of host cell lineages. Expressing clones from each host were fully characterized for product quality and productivity attributes, highlighting distinctions between the lineages.
Chapman Wright, Ph.D., Scientist II, Cell Culture Development, Biogen Idec

8:45
Case StudyNew Data
Comparison of Approaches for Early Screening of Stability of Production Cell Lines
Abstract not available at time of print.
Nitin Agarwal, Ph.D., Scientist II, Cell Culture & Fermentation Sciences, MedImmune

9:15
Case StudyNew Data
A Tale of Product Induced Clonal Instability and Utilization of Regulated Expression System
Clonal instability is mainly caused by DNA loss or silencing but occasionally by toxicity of the expressed proteins. We have developed a regulated expression system that produces at high titers, an antibody for which constitutive expression triggers clonal instability. Inducible Clones were stable in culture and post-thaw. Hence, regulated expression maybe suitable for production of proteins that trigger instability.
Shahram Misaghi, Ph.D., Scientist, Early Stage Cell Culture Department, Genentech, Inc.

9:45
Single Cell Derivation by Flow Cytometry and Regulated-Expression Yields Assurance of Clonality and Cell Line Stability
Cell line clonality and stability are the foundation of a robust therapeutic protein production process. Flow cytometry is the foundation of our cell line development process. FACS-based autologous secretion trap (FASTR) technology enables isolation of pools with desired growth and stable expression properties, and single cell isolation using flow cytometry ensures clonality. High cell productivity is often associated with low clone stability because the constitutive high-level expression of a secreted recombinant protein can result in a significant burden on normal cellular processes leading to a reduced growth rate, which in turn provides an opportunity for variant cells to increase in the cell population over time. We developed a novel inducible cell expression (NICE) system that facilitates isolation of clones with high specific productivities that retain stability without selective pressure and is amenable to scale up production
Dipali Deshpande, Ph.D., Staff Scientist, Protein Expression Sciences, Regeneron Pharmaceuticals Inc.

10:15
Networking Refreshment Break in Poster & Exhibit Hall

Integration at the Interfaces to Improve Speed and Quality of Cell Line Development

10:45
Case StudyNew Data
Integrated Cell Line and Process Development for a Difficult to Express Protein
New approaches in cell line and culture process development were utilized to increase expression of a difficult to express, positively charged protein by greater than 10-fold while maintaining product quality similar to early clinical material. A combination of multiple CHO hosts and 15mL automated bioreactors allowed for screening of 136 cell lines. Additionally, the protein's adherence to the cell surface required process additives to disrupt cell-protein interaction and improve cellular productivity.
Bryan St. Germain, M.S., Associate Scientist II, Cell Culture Development, Biogen Idec

11:15
Case StudyNew Data
Early-Stage Development of Bi-Specific Antibodies at Genentech
Abstract not available at time of print.
Andy Lin, Ph.D., Associate Director, Early Stage Cell Culture, Pharma Technical Development, Genentech, A Member of the Roche Group

11:45
Networking Luncheon in Poster & Exhibit Hall

12:55
Chairperson's Remarks
Andy Lin, Ph.D., Process Research & Development, Genentech, Inc.

Integration at the Interfaces to Improve Speed and Quality of Cell Line Development (continued)

1:00
Case Study
Towards a Better Fit of Cell Line and Process: The Impact of Uniting Archipelagos of Automation
Use of automation systems in process development is increasing rapidly and is becoming the industry expectation. Linking 'islands of automation' into 'archipelagos' provides a flexible approach to delivering more robust and well-understood processes. The paradigm shifts in cell line and process development made possible by bringing together automation platforms for cell culture, DSP and process analytics will be illustrated using examples from Lonza's experience developing automation archipelagos.
Andy Racher, Ph.D., Head of Process Development Sciences, Lonza Biologics, United Kingdom

1:30
Case StudyNew Data
Development of a New Higher Yielding Recombinant CHO Cell Line Utilizing Integrated Analytics to Ensure a Close CQA Match
Abstract not available at time of print.
Tarik Senussi, Ph.D., Scientist II, Cell Culture & Fermentation Sciences, MedImmune, United Kingdom

Improving Efficiency, Productivity and Timelines in Cell Line Development

2:00
New Data
Reducing Timelines and Increasing Titres by Identification of Host Cell Lines with Improved Characteristics
A host cell line plays an important role in determining characteristics of recombinant cell lines. At Fujifilm Diosynth Biotechnologies, directed evolution approaches (e.g. FACS enrichment of cells with extended viability and cloning) have been utilised to identify CHO host cell lines with improved characteristics. Here we present data from these approaches, including data comparing the performance of new host cell lines with an original host cell line.
Alison Porter, Ph.D., Head of Mammalian Cell Culture R&D, Fujifilm Diosynth Biotechnologies

2:30
New Data
New Approaches to Expedite Cell Line Development - Use of FACS Sorting and a Single Round of Cloning
Cell line development (CLD) remains on the critical path during development of biological drugs. On top, regulatory requirements to documentation, including raw materials and clonality status have increased. Boehringer-Ingelheim approaches this need for speed and need for quality and documentation with new screening and clone selection procedures to deliver high-expressing and stable BI-HEX clones. We will discuss the development of our current concept which uses chemically defined raw materials, a single round of 384-well plate FACS cloning, automated imaging and liquid handling as well as robust control testing.
Anne Tolstrup, Ph.D., Process Development & Strategy, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

3:00
Networking Refreshment Break and Last Chance for Poster & Exhibit Viewing

3:30
Case StudyNew Data
Targeting Integration of Transgenes to the CHO DHFR Locus
Although genome engineering technologies are rapidly evolving, site-specific integration in CHO cells remains challenging. We have identified a target site within the native DHFR locus of CHO cells that appears to provide high expression and genetic stability of transgenes. We have developed a variety of methods to target transgenes to this locus and discuss the impacts on gene expression and development timelines.
Michael G. Nicholson, Ph.D., Director of Cell Biology, Precision BioSciences

4:00
New Data
Fast Identification of Reliable Hosts for Targeted Cell Line Development from a Limited-Genome Screening Using Combined φC31 integrase and CRE-Lox Technologies
In this talk we will describe our non-viral based approach for quickly establishing target integration (TI) hosts for stable cell line development (CLD). Importantly, the TI hosts identified are consistent in supporting the production of diverse antibodies regardless of antibody subclass (IgG1 vs. IgG4) or prior traditional CLD performance (relatively easy vs. difficult to express). Further increase in titer (~2 fold or more) for the TI CLD can be achieved via vector optimization.
Yongping Crawford, Ph.D., Scientist, Early Stage Cell Culture, Genentech, Inc.

4:30
Case Study
Introducing STEP™(Selection Technology for Enhanced Production): A Novel Expression Platform Designed to Overcome Some of the Limitations of Current Therapeutic Protein Expression Systems
STEP™ achieves high protein expression levels without the need for time-consuming gene amplification and subsequent rounds of cell sub-cloning by means of a highly stringent selection system which can be tailored to different types of protein such that maximum expression levels are always achieved. The result is a system that generates very high producing CHO cell lines from a small number (typically 20-30) of clones eliminating the burden of extensive screening.
Femke Hoeksema, Ph.D., Team Leader, Cell Line Generation, Batavia Bioservices B.V., The Netherlands

5:00
Close of Day Two

Dinner Symposium (special registration required)

Additional registration fee required - see registration page for details

Please join us for this highly interactive 3 hour evening exchange in a roundtable format, which encourages participants to share their experiences and concerns amongst several discussion topics that include:

5:30
Discussion Groups
  • Future of Gene Editing Technologies Applied to Cell Line Engineering
    Moderator: Kevin J. Kayser, Ph.D., Director, Cell Sciences and Development, SAFC
  • Accelerating the Cell Line Development Timeline
    Moderator: Hilary Metcalfe, Ph.D., Head of Process Development, Lonza, United Kingdom
  • Current Practices To Provide Assurance Of Clonality
    Moderator: Andy Lin, Ph.D., Associate Director, Early Stage Cell Culture, Pharma Technical Development, Genentech, A Member of the Roche Group
  • Identifying CHO Cell Line Engineering Targets for Controlling Product Quality and Improving Process Performance
    Moderator: Rodney Combs, M.S., Associate Research Fellow, Bioprocess R&D, Culture Process Development, World Wide Pharmaceutical Sciences, Pfizer Inc.
  • CHO-Omics, NGS and Big Data: Next Generation Cell Line Development
    Moderator: Chapman Wright, Ph.D., Scientist II, Cell Culture Development, Biogen Idec

6:30
Dinner

7:30
Dessert and Summaries from Each Discussion

8:30
Close of Symposium

Wednesday, September 10, 2014

8:00
Chairman's Opening Remarks and Announcement of Poster Winners
Kevin J. Kayser, Ph.D., Director, Cell Sciences and Development, SAFC

Innovation with Transient and Problematic Cell Lines

8:15
Case Study
Advances in Transient Expression: Creating a High Yielding and Efficient Transient Expression
Advances in transient expression technology have led to the creation of a high yielding transient system. Creation, efficiency and potential of a proprietary high expression CHO transient system capable of expressing gram/litre of recombinant protein will be presented.
Lekan Daramola, Ph.D., Associate Director, Early Expression and Supply, Cell Culture and Fermentation Sciences, Biopharmaceutical Development, MedImmune, United Kingdom

8:45
Case StudyNew Data
High Density Transient Transfection System Based on GS-CHO Knockout Cell Line
We discuss the development of a PEI-mediated transient CHO-GS KO system capable of generating high yields, scalable up to 2L. This was achieved through rigorous optimization of cell density, DNA and PEI amounts followed by process development strategies. The newly developed method increased our average expression yield by ~4 fold relative to the existing transient HEK293 method.
Yashas Rajendra, Ph.D., Research Scientist, Biotechnology Discovery Research, Eli Lilly and Company

9:15
Case StudyNew Data
Reducing Risk and Building Success for Process Scale-Up of PER.C6 Processes within a Partnership
Biogen Idec and Janssen have partnered in transferring numerous products involving multiple cell lines from Janssen Development into all scales of Biogen Idec Manufacturing over the last four years. To increase the probability of success for tech transfer and scale-up, especially for problematic cell lines like PER.C6, the joint project teams have used a variety of tools: predictive process models to identify scale-up sensitivities, unique characterization of problematic raw materials, and the application of multivariate process analytics of both continuous and end of batch data models have resulted in significant improvement in lessons learned trends and created a more systematic framework for managing the risk of new process introductions.
Gene Schaefer, Ph.D., Senior Director, API - Large Molecule Development, Janssen Biologics R&D
Erik Hughes, Ph.D., Associate Director, Process Science Labs, Manufacturing Sciences, Biogen Idec

10:00
Case Study
Streamlining Biotherapeutic Development: From >1 g/L Antibody Titer to Rapid, High Yield Stable Pools and Stable Cell Lines
MaxCyte flow electroporation offers fully scalable, high-efficiency transient gene expression. Data will be presented demonstrating the reproducibility and scalability of MaxCyte flow electroporation and its capacity to produce antibody titers >1 g/L. In addition, data will be presented showing the use of flow electroporation for creation of the stable CHO pools and the rapid generation of high-yield stable cell lines within 6-8 weeks of transfection.
James Brady, Ph.D., Director of Technical Applications, MaxCyte, Inc.

10:30
Networking Refreshment Break

Cell Culture Media Development and Optimization

11:00
New Data
Evaluation of Alternatives to Animal Derived Reagents Used for Productivity Enrichment During Cell Line Development
The generation of high producing cell lines is a multistep process that involves several screening and enrichment steps with a variety of media and reagents that enable single cell growth and assessment of productivity. Most companies have successfully eliminated serum and other animal derived components from the media used to generate cell lines. Unfortunately, the industry still relies heavily on polyclonal antibodies as a selection tool for productivity enrichment steps such as FACS and ClonePix. With increased regulatory scrutiny being applied to these secondary exposures, implementing animal-free alternatives has become a necessity. Here we present our evaluation of several viable alternatives to polyclonal antibodies in both Clonepix and FACS enrichment methodologies.
Christina Alves, Ph.D., Scientist, Cell Culture Development, Biogen Idec

11:30
Case StudyNew Data
An Efficient DOE Approach for Developing In-House Chemically Defined Media
Design of experiment approach is powerful tool for the development of chemically-defined media. A few response surface designs will be discuss during this talk. Understanding the main effects, quadratic effects, and two-way interactions of media components on cell growth, productivity, and product quality are all important and achievable by these smart methodologies. Applying good DoE workflows can reduce time and experiments significantly.
Maria Ng, Scientist II, Cell Culture Process Development, BioMarin Pharmaceutical Inc.

12:00
Technology Workshop
For more information on presenting a Technology Workshop, please contact Jennifer Thebodo at 508-614-1672 or jthebodo@ibcusa.com

12:30
Lunch on Your Own

1:40
Chairperson's Remarks
Stephanie E. Reider, Ph.D., Principal Research Scientist, Biologics, AbbVie Bioresearch Center (invited)

Developing Cell Lines for Biosimilars

1:45
Case Study
Approaches to Match Product Quality Attributes
The development of biosimilars starts with definition of the molecular characteristics and quality attributes of an approved biotech product with known clinical and safety profiles. This information sets the goal posts for the development of a scaleable, validatable and economical process for a biosimilar. This talk will concentrate on the connection between cell line and quality attributes and discusses methods to improve the "match" in quality attributes between the brand and the biosimilar products when designing and selecting the cell line.
Marcio Voloch, Ph.D., Vice President, Process Development, Momenta

2:15
Case Study
Biosimilar Cell Line Development
Biosimilar cell line development is a multi-step process, based on quality by design principles. Systematic approach, mainly being driven by a continuous iterative loop between cell line/process development and product analytical characterization, results in desired product quality. Different novel technologies such as next generation sequencing and cell line genetic modifications are being implemented for further cell line and product quality improvements.
Dominik Gaser, Ph.D., Head, Cell and Molecular Biology, Sandoz

2:45
Networking Refreshment Break

Cell Line Development and Modification for Novel Modalities and Difficult-to-Express Proteins

3:00
New Data
Unfolded Protein Response and the Response of Cells to Making Difficult Proteins
The endoplasmic reticulum (ER) is specialized for folding and modification of proteins. Protein folding in the ER requires extensive energy and formation of disulfide bonds. Accumulation of misfolded protein activates the adaptive unfolded protein response (UPR) transmitted through transmembrane sensors; IRE1, ATF6, and PERK. If unresolvable, cells activate cell death. The mechanism(s) that dictate survival vs death will be described.
Randy J. Kaufman, Ph.D., Director, Degenerative Diseases Research, Sandford Burnham Medical Research Institute

3:30
Case StudyNew Data
Cell Line Development Approaches for Expression of Bispecific DART® Molecules
Dual-Affinity Re-Targeting (DART) molecules are antibody-like therapeutic proteins that can target multiple different epitopes. These molecules have excellent product stability, optimal chain pairing, predictable antigen-recognition, and customizable half-life in vivo. Several protein and cell-line engineering strategies have been developed to achieve correct molecule assembly, high expression levels, and biological activity of these complex, multi-chain proteins. Data will be presented from case studies for the expression of two DART proteins with different structures and target specificities.
Valentina Ciccarone, Ph.D., Principal Scientist, Cell Line Development, Macrogenics, Inc.

4:00
Case StudyNew Data
Generation of a Stable CHO-K1 Cell Line for a Novel 2+2 Crossmab Format Antibody
We have generated a recombinant, stable CHO-K1 based cell line for a novel 2+2 CrossMab antibody. The application of our cell line development platform comprising semi-automation and a diligent cell line selection strategy resulted in final cell clones with a stable product profile and high product quality. In the talk we describe the strategy and execution of the cell line generation process and discuss differences between generation of cell lines for standard versus complex format antibodies.
Stefan Seeber, Ph.D., Principal Scientist, Dept. Cell Line and Molecule Development, Roche Pharma Research and Development (pRED)

4:30
Close of Conference